We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

TSRO
Tesaro, Inc.
NasdaqGS
People also watch : CLVS PTLA EPZM PBYI PTCT
93.24 -0.38 (-0.41%)

After hours: 93.260.02 (0.02%) as of 4:48 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close 93.62
Open 93.00
Bid 92.72 x 100
Ask 99.84 x 200
52wk Range 29.51 - 94.48
Day's Range 91.18 - 93.83
Volume 1,123,109
Avg Vol (3m) 1,161,969
As of 4:00 PM EDT. Market closed.
  • Barrons.com 7 days ago

    Gilead Has a Problem. These Three Biotechs Could Be the Solution

    Guggenheim's Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales: ...[When] looking at consensus estimates through 2020, there is a slight, though continuous, decline in overall revenue with EPS remaining largely flat, likely due to share repurchases. With approximately $16 billion in operating cash flow annually and more than $21 billion in cash and short-term assets on the balance sheet, Gilead has a good deal of capital to deploy to boost its revenues. Most questions we receive on Gilead regard what should it “buy.” What type of business development activity should Gilead engage in that will support possibly higher future revenues?

  • Kiplinger 14 days ago

    10 Stocks That Could Ruin Your Retirement

    Many of these stocks don't belong with other retirement holdings simply because the risk is too high.

  • A Big Breakthrough for Ovarian Cancer Patients
    Motley Fool 26 days ago

    A Big Breakthrough for Ovarian Cancer Patients

    Tesaro's PARP-inhibitor niraparib just delivered remarkable results when used in previously treated ovarian cancer patients.

  • An Overnight Double! Could These Drugmakers Be Next?
    Motley Fool 28 days ago

    An Overnight Double! Could These Drugmakers Be Next?

    The PARP inhibitor space is hot.

  • American City Business Journals 28 days ago

    ​Tesaro raises $377M in largest local biotech stock offering in the past year

    Waltham drugmaker Tesaro wasted no time after announcing stellar late-stage trial results from its ovarian cancer drug before putting the resultant stock spike to good use with a $377 million stock offering. The secondary offering of 4.7 million shares by Tesaro (TSRO) valued at $81 each is the largest to be raised by a local biotech company since the sector began a significant selloff nearly a year ago. The last offering by a local drug developer that was of equal or greater size was a $450 million offering raised by Alnylam Pharmaceuticals (ALNY) in January 2015.

  • Tesaro (TSRO) in Focus: Stock Adds 8.6% in Session
    Zacks 28 days ago

    Tesaro (TSRO) in Focus: Stock Adds 8.6% in Session

    Tesaro, Inc. (TSRO) shares rose almost 9% in the last trading session.

  • Tesaro Stock Up on Successful Phase III Ovarian Cancer Trial
    Zacks 29 days ago

    Tesaro Stock Up on Successful Phase III Ovarian Cancer Trial

    Shares of Tesaro, Inc. (TSRO) surged 108% after the company announced that its phase III trial, NOVA, on oncology drug niraparib successfully achieved the primary endpoint of progression-free survival (PFS).

  • Here’s Why Traders Are Buzzing Around Lions Gate, Stellar Biotechnologies, and Three Other Stocks
    Insider Monkey 29 days ago

    Here’s Why Traders Are Buzzing Around Lions Gate, Stellar Biotechnologies, and Three Other Stocks

    Stocks are trading in the green on Thursday as markets continue to steadily recover from the Brexit-triggered wild swings. However, investors remain selective as the future of the global economy is still dotted with uncertainties after UK’s exit from the European Union. Meanwhile, some stocks are worth watching closely today, including TESARO Inc (NASDAQ:TSRO), Stellar […]

  • TheStreet.com 29 days ago

    Protect Gains Into the Holiday Weekend

    There can be good small-cap trading, but stay selective.

  • TheStreet.com 29 days ago

    Dr. Marc Siegel Explains Why Tesaro (TSRO) Cancer Drug Is a Big Deal

    In most cases ovarian cancer recurs within two years after chemotherapy, but the Tesaro (TSRO) drug stops that, Dr. Marc Siegel explained on Fox Business today.